CA2068221A1 - Dosage direct de la fibrinogene - Google Patents

Dosage direct de la fibrinogene

Info

Publication number
CA2068221A1
CA2068221A1 CA002068221A CA2068221A CA2068221A1 CA 2068221 A1 CA2068221 A1 CA 2068221A1 CA 002068221 A CA002068221 A CA 002068221A CA 2068221 A CA2068221 A CA 2068221A CA 2068221 A1 CA2068221 A1 CA 2068221A1
Authority
CA
Canada
Prior art keywords
plasma
fibrinogen
sample
concentration
delta value
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002068221A
Other languages
English (en)
Inventor
Julie Frances Hoffman
Janet Black Callahan
Charles Hermas Swope
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo NV
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2068221A1 publication Critical patent/CA2068221A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/84—Systems specially adapted for particular applications
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/75—Fibrin; Fibrinogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Plasma & Fusion (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002068221A 1989-12-01 1990-11-30 Dosage direct de la fibrinogene Abandoned CA2068221A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44394889A 1989-12-01 1989-12-01
US443,948 1989-12-01

Publications (1)

Publication Number Publication Date
CA2068221A1 true CA2068221A1 (fr) 1991-06-02

Family

ID=23762843

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002068221A Abandoned CA2068221A1 (fr) 1989-12-01 1990-11-30 Dosage direct de la fibrinogene

Country Status (9)

Country Link
EP (1) EP0502103A4 (fr)
JP (1) JPH05503008A (fr)
KR (1) KR920704117A (fr)
AU (1) AU641459B2 (fr)
CA (1) CA2068221A1 (fr)
FI (1) FI922312A (fr)
IE (1) IE904244A1 (fr)
WO (1) WO1991008460A1 (fr)
ZA (1) ZA909564B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5708591A (en) * 1995-02-14 1998-01-13 Akzo Nobel N.V. Method and apparatus for predicting the presence of congenital and acquired imbalances and therapeutic conditions
US6429017B1 (en) 1999-02-04 2002-08-06 Biomerieux Method for predicting the presence of haemostatic dysfunction in a patient sample
US6898532B1 (en) 1995-06-07 2005-05-24 Biomerieux, Inc. Method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample
US6321164B1 (en) 1995-06-07 2001-11-20 Akzo Nobel N.V. Method and apparatus for predicting the presence of an abnormal level of one or more proteins in the clotting cascade
US6502040B2 (en) 1997-12-31 2002-12-31 Biomerieux, Inc. Method for presenting thrombosis and hemostasis assay data
AU774889B2 (en) 1999-02-04 2004-07-08 Biomerieux, Inc. A method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample
US7179612B2 (en) 2000-06-09 2007-02-20 Biomerieux, Inc. Method for detecting a lipoprotein-acute phase protein complex and predicting an increased risk of system failure or mortality
CN110257475B (zh) * 2019-06-28 2023-05-02 深圳市国赛生物技术有限公司 纤维蛋白原检测试剂及其制备方法及检测试剂制品

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3432268A (en) * 1964-08-28 1969-03-11 Peter Unger Method and apparatus for testing cell suspensions
US3658480A (en) * 1970-04-13 1972-04-25 Bio Data Corp Coagulation timing apparatus, and method
US3833864A (en) * 1972-11-30 1974-09-03 R Kiess Digital direct reading colorimeter
US3861877A (en) * 1974-01-21 1975-01-21 Clinical Technology Inc Optical analysis of fluids
US3905769A (en) * 1974-02-28 1975-09-16 Bagley Wallace E Method and apparatus for measuring prothrombin time and the like
US3989382A (en) * 1975-01-22 1976-11-02 Bio-Data Corporation Platelet aggregation monitoring device
EP0059277A1 (fr) * 1981-03-02 1982-09-08 J. & P. Coats, Limited Procédé pour la mesure quantitative rapide du fibrinogène dans le plasma sanguin
AT382971B (de) * 1981-06-16 1987-05-11 Hoffmann La Roche Verfahren und vorrichtung zur messung der blutgerinnungszeit
GB8426004D0 (en) * 1984-10-15 1984-11-21 Ortho Diagnostic Systems Inc Coagulation monitoring
IT1209604B (it) * 1984-11-27 1989-08-30 Instrumentation Lab Spa Metodo ed apparecchiatura per la misura di parametri di coagulazione.

Also Published As

Publication number Publication date
AU6898391A (en) 1991-06-26
KR920704117A (ko) 1992-12-19
FI922312A0 (fi) 1992-05-21
WO1991008460A1 (fr) 1991-06-13
ZA909564B (en) 1992-11-25
AU641459B2 (en) 1993-09-23
FI922312A (fi) 1992-05-21
EP0502103A1 (fr) 1992-09-09
JPH05503008A (ja) 1993-05-27
IE904244A1 (en) 1991-06-05
EP0502103A4 (en) 1993-05-05

Similar Documents

Publication Publication Date Title
Tripodi et al. Are capillary whole blood coagulation monitors suitable for the control of oral anticoagulant treatment by the international normalized ratio?
US4252536A (en) Method and system for measuring blood coagulation time
US4047890A (en) Method and apparatus for determining deficiencies in enzymatic reactors particularly clotting factor levels in blood plasmas
US4720787A (en) Methods for coagulation monitoring
Teien et al. Heparin assay in plasma: A comparison of five clotting methods
US3905769A (en) Method and apparatus for measuring prothrombin time and the like
US5197017A (en) Potentiophotometric fibrinogen determination
Chandler et al. Comparison of three methods for measuring factor VIII levels in plasma
EP0137269A1 (fr) Procédé pour la détermination simultanée de fibrinogène et de produits du clivage du fibrinogène dans le plasma
JP2938302B2 (ja) 血液凝固時間測定方法とその装置
WO1991008461A1 (fr) Procede de controle de l'alimentation en reactif dans un spectrophotometre a balayage
CA2068221A1 (fr) Dosage direct de la fibrinogene
EP4239078A1 (fr) Procédé de détection d'une réaction de coagulation sanguine
Griepink Improving the quality of environmental trace analysis
US5223437A (en) Direct fibrinogen assay
Massignon et al. Prothrombin time sensitivity and specificity to mild clotting factor deficiencies of the extrinsic pathway: evaluation of eight commercial thromboplastins
US20040219680A1 (en) Method and apparatus for determining anticoagulant therapy factors
Miller et al. Evaluation of two automated methods for measurement of the ristocetin cofactor activity of von Willebrand factor
Vacas et al. Comparative study of a portable prothrombin time monitor employing three different systems in oral anticoagulant units
EP0062616A1 (fr) Procédé pour étudier la coagulation du sang et l'aggrégation des plaquettes sanguines et dispositif pour la mise en oeuvre de ce procédé
JPS63305255A (ja) 血液凝固能測定方法
CN116057383A (zh) 凝血反应的分析方法
Leeming et al. The determination of INR in stored whole blood.
CA1062501A (fr) Methode et appareil pour depister les deficiences au niveau des reactions enzymatiques et particullerement les taux de facteurs de coagulation dans le plasma sanguin
Junker et al. Interferences in coagulation tests–evaluation of the 570-nm method on the Dade Behring BCS analyser

Legal Events

Date Code Title Description
FZDE Dead